Trial Profile
Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1060469 in Healthy Asian Male Volunteers in a Randomized, Double-blind, Placebo-controlled Design
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Jan 2017
Price :
$35
*
At a glance
- Drugs BI 1060469 (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 15 Oct 2014 Status changed from recruiting to completed, as reported by ClinicalTrials.gov record
- 14 Aug 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 13 Jul 2014 New trial record